The US firm said as per its policy, the company only deals with central governments. "When the COVID cases and the number of deaths started sky-rocketing towards the end of April 2021, the GOI abruptly changed the vaccination policy and stated that the states will have to make their own arrangements for vaccinating the youth", the letter read.
"An increase in vaccine choices is desirable", Chief Cabinet Secretary Katsunobu Kato said at a news conference, adding that the approval process is expected to be rapidly carried out, with priority on confirming the vaccine's efficacy and safety.
"We will submit these results to the U.S. FDA and regulators globally in early June and request authorization", said Stéphane Bancel, Chief Executive Officer of Moderna. Earlier this month, the U.S. Food and Drug Administration expanded clearance of the Pfizer Inc.
Moderna, too, is said to have told the Punjab government that it would deal only with the Centre.
Moderna's study included 3,732 adolescents from ages 12 to 17 enrolled at sites across the U.S.
The vaccine candidate, known as mRNA-1273, was given as two doses four weeks apart with half of the group given the jab and half given the placebo. That data found the vaccine was 96% effective starting 14 days after the first dose.
This included against both symptomatic and asymptomatic illness.
An industry representative explained:, since vaccines have emergency authorisations in most countries, they will be available only through government channels - meaning, there is no excess stock to tap.
Other common symptoms were fatigue, headache, muscle pain and chills, but no serious side effects were reported.
Currently, Moderna's vaccine is only available for Americans aged 18 and older because the initial clinical trial only included adults.
It could also help boost vaccination rates with more than 25 million adolescents between ages 12 and 17 in the US, according to data from the Census Bureau.
"Pfizer will supply COVID-19 vaccine only to central governments and supra-national organisations for deployment in national immunization programs".
Only about three in 10 parents - 29 percent - of children under 18 said they would get their child vaccinated 'right away'. A Pfizer spokesperson had also told this newspaper in December that the company would only deal with the government.
While children are far less likely than adults to get seriously ill from the coronavirus, they represent about 14% of the nation's COVID-19 cases. At least 316 have died in the US alone, according to a tally by the American Academy of Pediatrics.